The Lymphoma Academic Research Organisation

This phase 3 trial tests whether a combination of two drugs, Mosunetuzumab and Lenalidomide, works better than standard treatments for marginal zone lymphoma that has come back or stopped responding. About 260 adults who have had at least one prior treatment will be randomly assi…

This study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer. About 60 adults…

This study compares a new combination of two drugs (mosunetuzumab and lenalidomide) against standard chemotherapy for people with untreated follicular lymphoma. About 790 participants will be randomly assigned to one of the two treatments. The goal is to see if the new combo keep…

This study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…

This study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…

This phase 2 trial is testing a combination of three drugs—glofitamab, venetoclax, and zanubrutinib—in people with high-risk mantle cell lymphoma, either newly diagnosed or after relapse. The study will enroll 100 participants across three groups based on their treatment history.…

This study looks back at medical records of about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients…

This study is a registry that collects information on people with blood cancers who are eligible for CAR-T cell therapy. It will track up to 5,000 patients in France to see how long they live, how well the treatment works, and how long it takes to start therapy. The goal is to le…

This registry is collecting information from women in France and Belgium who have a rare type of lymphoma linked to breast implants. The goal is to learn more about the disease, how it responds to treatment, and how to improve care. No new treatments are being tested; instead, re…